Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-05-2004 | Editorial

Has PET become an important clinical tool in paediatric imaging?

Authors: Klaus Hahn, Thomas Pfluger

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2004

Excerpt

In adults, positron emission tomography (PET) has become an indispensable imaging tool in clinical nuclear medicine. Especially in combination with computed tomography (CT) and magnetic resonance imaging (MRI), it is an established method in the fields of neurology, cardiology, infectiology and oncology. Compared with its widespread application in adults, however, clinical use of PET in paediatrics is still very limited. Possible reasons include the small number of clinical and prospective studies of PET’s potential in paediatric as compared to adult imaging. Furthermore, only a few PET scanners are available for paediatric imaging. Our goal in this editorial is to examine and summarise reports in the literature concerning the clinical application of PET in paediatric neurology, cardiology, infectiology and oncology. …

Shulkin BL. PET applications in pediatrics. Q J Nucl Med 1997; 4:281–291.

O’Hara SM, Donnelly LF, Coleman RE. Pediatric body applications of FDG PET. AJR Am J Roentgenol 1999; 172:1019–1024.PubMed

Borgwardt L, Jung Larsen H, Pedersen K, Højgaard L. Practical use and implementation of PET in children in a hospital PET centre Eur J Nucl Med Mol Imaging 2003; 30:1389–1397.CrossRef

Yeung HW, Sanches A, Squire OD, Macapinlac HA, Larson SM, Erdi YE. Standardized uptake value in pediatric patients: an investigation to determine the optimum measurement parameter. Eur J Nucl Med Mol Imaging 2002; 29:61-66.

Ruotsalainen U, Suhonen-Polvi H, Eronen E, Kinnala A, Bergman J, Haaparanta M, Teras M, Solin O, Wegelius U. Estimated radiation dose to the newborn in FDG-PET studies. J Nucl Med 1996; 37:387–393.PubMed

Mohan KK, Chugani DC, Chugani HT. Positron emission tomography in pediatric neurology. Semin Pediatr Neurol 1999; 6:111–119.PubMed

Chugani HT, Phelps ME, Mazziotta JC. Positron emission tomography study of human brain functional development. Ann Neurol 1987; 22:487–497.PubMed

Muller RA, Behen ME, Rothermel RD, Muzik O, Chakraborty PK, Chugani HT. Brain organization for language in children, adolescents, and adults with left hemisphere lesion: a PET study. Prog Neuropsychopharmacol Biol Psychiatry 1999; 23:657–668.CrossRefPubMed

Suhonen-Polvi H, Ruotsalainen U, Kinnala A, Bergman J, Haaparanta M, Teras M, Makel a P, Solin O, Wegelius U. FDG-PET in early infancy: simplified quantification methods to measure cerebral glucose utilization. J Nucl Med 1995; 36:1249–1254.

10.

O’Tuama LA, Dickstein DP, Neeper R, Gascon GG. Functional brain imaging in neuropsychiatric disorders of childhood. J Child Neurol 1999; 14:207–221.

11.

Fois A, Farnetani MA, Balestri P, Buoni S, Di Cosmo G, Vattimo A, Guazzelli M, Guzzardi R, Salvadori PA. EEG, PET, SPET and MRI in intractable childhood epilepsies: possible surgical correlations. Childs Nerv Syst 1995; 11:672–678.PubMed

12.

Won HJ, Chang KH, Cheon JE, Kim HD, Lee DS, Han MH, Kim IO, Lee SK, Chung CK. Comparison of MR imaging with PET and ictal SPECT in 118 patients with intractable epilepsy. AJNR Am J Neuroradiol 1999; 20:593–599.PubMed

13.

Muzik O, da Silva EA, Juhasz C, Chugani DC, Shah J, Nagy F, Canady A, von Stockhausen HM, Herholz K, Gates J, Frost M, Ritter F, Watson C, Chugani HT. Intracranial EEG versus flumazenil and glucose PET in children with extratemporal lobe epilepsy. Neurology 2000; 54:171–179.PubMed

14.

Meltzer CC, Adelson PD, Brenner RP, Crumrine PK, Van Cott A, Schiff DP, Townsend DW, Scheuer ML. Planned ictal FDG PET imaging for localization of extratemporal epileptic foci. Epilepsia 2000; 41:193–200.PubMed

15.

Engel J Jr, Kuhl DE, Phelps ME. Patterns of human local cerebral glucose metabolism during epileptic seizures. Science 1982; 218:64–66.PubMed

16.

Kim SK, Wang KC, Hwang YS, Kim KJ, Kim IO, Lee DS, Yi Y, Cho BK. Pediatric intractable epilepsy: the role of presurgical evaluation and seizure outcome. Childs Nerv Syst 2000; 16:278–285.CrossRefPubMed

17.

Snead OC 3rd, Chen LS, Mitchell WG, Kongelbeck SR, Raffel C, Gilles FH, Nelson MD Jr. Usefulness of [¹⁸F]fluorodeoxyglucose positron emission tomography in pediatric epilepsy surgery. Pediatr Neurol 1996; 14:98–107.CrossRefPubMed

18.

Holopainen IE, Lundbom NM, Metsahonkala EL, Komu ME, Sonninen PH, Haaparanta MT, Bergman JR, Sillanpaa ML. Temporal lobe pathology in epilepsy: proton magnetic resonance spectroscopy and positron emission tomography study. Pediatr Neurol 1997; 16:98–104.CrossRefPubMed

19.

Bentourkia M, Michel C, Ferriere G, Bol A, Coppens A, Sibomana M, Bausart R, Labar D, De Volder AG. Evolution of brain glucose metabolism with age in epileptic infants, children and adolescents. Brain Dev 1998; 20:524–9CrossRefPubMed

20.

Gaillard WD, Kopylev L, Weinstein S, Conry J, Pearl PL, Spanaki MV, Fazilat S, Fazilat S, Venzina LG, Dubovsky E, Theodore WH. Low incidence of abnormal (18)FDG-PET in children with new-onset partial epilepsy: a prospective study. Neurology 2002; 58:717–22PubMed

21.

22.

Fedi M, Reutens DC, Andermann F, Okazawa H, Boling W, White C, Dubeau F, Nakai A, Gross DW, Andermann E, Diksic M. alpha-[¹¹C]-Methyl-l-tryptophan PET identifies the epileptogenic tuber and correlates with interictal spike frequency. Epilepsy Res 2003; 52:203–213.CrossRefPubMed

23.

Fiorella DJ, Provenzale JM, Coleman RE, Crain BJ, Al-Sugair AA. (18)F fluorodeoxyglucose positron emission tomography and MR imaging findings in Rasmussen encephalitis. AJNR Am J Neuroradiol 2001; 22:1291–1299.PubMed

24.

Lee JS, Juhasz C, Kaddurah AK, Chugani HT. Patterns of cerebral glucose metabolism in early and late stages of Rasmussen’s syndrome. J Child Neurol 2001; 16:798–805.PubMed

25.

Depas G, Chiron C, Tardieu M, Nuttin C, Blanche S, Raynaud C, Syrota A. Functional brain imaging in HIV-1-infected children born to seropositive mothers. J Nucl Med 1995; 36:2169–2174.

26.

Thorngren-Jerneck K, Ohlsson T, Sandell A, Erlandsson K, Strand SE, Ryding E, Svenningsen NW. Cerebral glucose metabolism measured by positron emission tomography in term newborn infants with hypoxic ischemic encephalopathy. Pediatr Res 2001; 49:495–501.PubMed

27.

Lee JS, Asano E, Muzik O, Chugani DC, Juhasz C, Pfund Z, Philip S, Behen M, Chugani HT. Sturge-Weber syndrome: correlation between clinical course and FDG PET findings. Neurology 2001; 57:189–195.PubMed

28.

Villemagne P, Naidu S, Villemagne VL, Yaster M, Wagner HN Jr, Harris JC, Moser HW, Johnston MV, Dannals RF, Wong DF. Brain glucose metabolism in Rett syndrome. Pediatr Neurol 2002; 27:117–122.CrossRefPubMed

29.

Castelnau P, Zilbovicius M, Ribeiro MJ, Hertz-Pannier L, Ogier H, Evrard P. Striatal and pontocerebellar hypoperfusion in Hallervorden-Spatz syndrome. Pediatr Neurol 2001; 25:170–174.CrossRefPubMed

30.

Kaplan AM, Chen K, Lawson MA, Wodrich DL, Bonstelle CT, Reiman EM. Positron emission tomography in children with neurofibromatosis-1. J Child Neurol 1997; 12:499–506.PubMed

31.

Rintahaka PJ, Chugani HT. Clinical role of positron emission tomography in children with tuberous sclerosis complex. J Child Neurol 1997; 12:42–52.

32.

Ernst M, Zametkin AJ, Matochik JA, Pascualvaca D, Jons PH, Cohen RM. High midbrain [¹⁸F]DOPA accumulation in children with attention deficit hyperactivity disorder. Am J Psychiatry 1999; 156:1209–1215.PubMed

33.

Delvenne V, Lotstra F, Goldman S, Biver F, De Maertelaer V, Appelboom-Fondu J, Schoutens A, Bidaut LM, Luxen A, Mendelwicz J. Brain hypometabolism of glucose in anorexia nervosa: a PET scan study. Biol Psychiatry 1995; 37:161–169.CrossRefPubMed

34.

Delvenne V, Goldman S, Simon Y, De Maertelaer V, Lotstra F. Brain hypometabolism of glucose in bulimia nervosa. Int J Eat Disord 1997; 21:313–320.CrossRefPubMed

35.

Reed W, Jagust W, Al-Mateen M, Vichinsky E. Role of positron emission tomography in determining the extent of CNS ischemia in patients with sickle cell disease. Am J Hematol 1999; 60:268–272.CrossRefPubMed

36.

Worley G, Hoffman JM, Paine SS, et al. 18-Fluorodeoxyglucose positron emission tomography in children and adolescents with traumatic brain injury. Dev Med Child Neurol 1995; 37:213–220.PubMed

37.

Reske SN, Kotzerke J. FDG-PET for clinical use. Eur J Nucl Med 2000; 28:1707–1723.CrossRef

38.

Kaplan AM, Lawson MA, Spataro J, Bandy DJ, Bonstelle CT, Moss SD, Manwaring KH, Reiman EM. Positron emission tomography using [¹⁸F] fluorodeoxyglucose and [¹¹C]l-methionine to metabolically characterize dysembryoplastic neuroepithelial tumors. J Child Neurol 1999; 14:673–677.PubMed

39.

Kaplan AM, Bandy DJ, Manwaring KH, Chen K, Lawson MA, Moss SD, Duncan JD, Wodrich DL, Schnur JA, Reiman EM. Functional brain mapping using positron emission tomography scanning in preoperative neurosurgical planning for pediatric brain tumors. J Neurosurg 1999; 91:797–803.PubMed

40.

Kahkonen M, Metsahonkala L, Minn H, Utriainen T, Korhonen T, Norvasuo-Heila MK, Harila-Saari A, Aarimaa T, Suhonen-Polvi H, Ruotsalainen U, Solin O, Salmi TT. Cerebral glucose metabolism in survivors of childhood acute lymphoblastic leukemia. Cancer 2000; 88:693–700.CrossRefPubMed

41.

Inoue T, Shibasaki T, Oriuchi N, Aoyagi K, Tomiyoshi K, Amano S, Mikuni M, Ida I, Aoki J, Endo K.¹⁸F-alpha-methyl tyrosine PET studies in patients with brain tumors. J Nucl Med 1999; 40:399–405.

42.

Utriainen M, Metsahonkala L, Salmi TT, Utriainen T, Kalimo H, Pihko H, Makipernaa A, Harila-Saari A, Jyrkkio S, Laine J, Nagren K, Minn H. Metabolic characterization of childhood brain tumors: comparison of¹⁸F-fluorodeoxyglucose and ¹¹C-methionine positron emission tomography. Cancer 2002; 95:1376–1386.CrossRefPubMed

43.

Vander Borght T, Pauwels S, Lambotte L, Labar D, De Maeght S, Stroobandt G, Laterre C. Brain tumor imaging with PET and 2-[carbon-11]thymidine. J Nucl Med 1994; 35:974–982.PubMed

44.

Molenkamp G, Riemann B, Kuwert T, Strater R, Kurlemann G, Schober O, Jurgens H, Wolff JE. Monitoring tumor activity in low grade glioma of childhood. Klin Padiatr 1998; 210:239–242.PubMed

45.

Maria BL, Drane WE, Mastin ST, Jimenez LA. Comparative value of thallium and glucose SPECT imaging in childhood brain tumors. Pediatr Neurol 1998; 19:351–357.CrossRefPubMed

46.

Skehan SJ, Issenman R, Mernagh J, Nahmias C, Jacobson K.¹⁸F-fluorodeoxyglucose positron tomography in diagnosis of paediatric inflammatory bowel disease. Lancet 1999; 354:836–837.PubMed

47.

Gungor T, Engel-Bicik I, Eich G, Willi UV, Nadal D, Hossle JP, Seger RA, Steinert HC. Diagnostic and therapeutic impact of whole body positron emission tomography using fluorine-18-fluoro-2-deoxy-d-glucose in children with chronic granulomatous disease. Arch Dis Child 2001; 85:341–345.CrossRefPubMed

48.

Muller AE, Kluge R, Biesold M, Rieske K, Korholz D. Whole body positron emission tomography detected occult infectious foci in a child with acute myeloid leukaemia. Med Pediatr Oncol 2002; 38:58–59.CrossRefPubMed

49.

Tomas MB, Tronco GG, Karayalcin G, Palestro CJ. FDG uptake in infectious mononucleosis. Clin Positron Imaging 2000; 3:176.CrossRefPubMed

50.

Franzius C, Biermann M, Hulskamp G, Frosch M, Roth J, Sciuk J, Schober O. Therapy monitoring in aspergillosis using F-18 FDG positron emission tomography. Clin Nucl Med 2001; 26:232–233.CrossRefPubMed

51.

Hauser M, Bengel FM, Kuhn A, Sauer U, Zylla S, Braun SL, Nekolla SG, Oberhoffer R, Lange R, Schwaiger M, Hess J. Myocardial blood flow and flow reserve after coronary reimplantation in patients. Circulation 2001; 103:1875–1880.PubMed

52.

Rickers C, Sasse K, Buchert R, Stern H, van den Hoff J, Lubeck M, Weil J. Myocardial viability assessed by positron emission tomography in infants and children after the arterial switch operation and suspected infarction. J Am Coll Cardiol 2000; 36:1676–1683.CrossRefPubMed

53.

Singh TP, Muzik O, Forbes TF, Di Carli MF. Positron emission tomography myocardial perfusion imaging in children with suspected coronary abnormalities. Pediatr Cardiol 2003; 24:138–144.CrossRefPubMed

54.

Litvinova II, Litvinov M, Leonteva II, Sebeleva II. 18. PET for diagnosis of mytochondrial cardiomyopathy in children. Clin Positron Imaging 2000; 3:172.CrossRefPubMed

55.

Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS. 18. 6-[¹⁸F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 2001; 38:6–8PubMed

56.

Kreissig R, Amthauer H, Krude H, Steinmueller P, Stroszczynski C, Hosten N, Grueters A, Felix R. The use of FDG-PET and CT for the staging of adrenocortical carcinoma in children. Pediatr Radiol 2000; 30:306.CrossRefPubMed

57.

Reske SN, Kotzerke J. FDG-PET for clinical use—results of the 3rd German Interdisciplinary Consensus Conference, ‘Onko-PET III’, 21 July and 19 September 2000. Eur J Nucl Med 2001; 28:1701–1723.

58.

Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) PET in nodal staging. Radiology 1997; 203:795–800.PubMed

59.

Körholz D, Kluge R, Wickmann L, Hirsch W, Lüders H, Lotz I, Dannenberg C, Hasenclever D, Dörffel W, Sabri O. Importance of F18-Fluorodeoxy-d-2-glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin’s lymphoma in childhood and adolescence—consequences for the GPOH-HD 2003 protocol. Onkologie 2003; 26:489–493.CrossRefPubMed

60.

Partridge S, Timothy A, O’Doherty MJ, Hain SF, Rankin S, Mikhael G. Fluorine-18-fluoro-2-deoxy-d-glucose positron emission tomography in the pretreatment staging of Hodgkin’s disease: influence on patient management in a single institution. Ann Oncol 2000; 11:1273–1279.PubMed

61.

Rini JN, Manalili EY. Hoffman MA, Karayalcin G, Mehrotra B, Thomas MB, Palestro CJ. F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin’s disease. Clin Nucl Med 2002; 27:572–577.

62.

Jerusalem G, Begun Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G. Whole-body positron emission tomography using¹⁸F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease. Haematologica 2001; 86:266–273.PubMed

63.

Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, Vanuytsel L, Bormans G, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G. Prognostic value of positron emission tomography (PET) with fluorine-18-fluorodeoxyglucose ([¹⁸F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [¹⁸F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19:414–419.PubMed

64.

Römer W, Hanauske AR, Ziegler S, Thodtmann R, Weber W, Fuchs C, Enne W, Herz M, Nerl C, Garbrecht M, Schwaiger M. Positron emission tomography in non-Hodgkin’s lymphoma: assessment of chemotherapy with FDG. Blood 1998; 91:4464–4471.PubMed

65.

Kostakoğlu L, Coleman M, Leonhard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 2002; 43:1018–1027.PubMed

66.

Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998; 16:603–609.PubMed

67.

Franzius C, Schulte M, Hillmann A, Winkelmann W, Jurgens H, Bockisch A, Schober O. [Clinical value of positron emission tomography (PET) in the diagnosis of bone and soft tissue tumors. 3rd Interdisciplinary Consensus Conference “PET in Oncology”: results of the Bone and Soft Tissue Study Group]. Chirurg 2001; 72:1071–1077.PubMed

68.

Daldrup-Link HE, Franzius C, Link TM, Laukamp D, Sciuk J, Jurgens H, Schober O, Rummeny EJ. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001; 177:229–236.

69.

Franzius C, Daldrup-Link HE, Sciuk J, Rummeny EJ, Bielack S, Jurgens H, Schober O. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 2001; 12:479–486.CrossRefPubMed

70.

Franzius C, Sciuk J, Daldrup-Link HE, Jurgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 2000; 27:1305–1311.PubMed

71.

Watanabe H, Shinozaki T, Yanagawa T, Aoki J, Tokunaga M, Inoue T, Endo K, Mohara S, Sano K, Takagishi K. Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning. J Bone Joint Surg Br 2000; 82:760–767.PubMed

72.

Wu H, Dimitrakopoulou-Strauss A, Heichel TO, Lehner B, Bernd L, Ewerbeck V, Burger C, Strauss LG. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis. Eur J Nucl Med 2001; 28:704–710.

73.

Franzius C, Daldrup-Link HE, Wagner-Bohn A, Sciuk J, Heindel WL, Jurgens H, Schober O. FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann Oncol 2002; 13:157–160.CrossRefPubMed

74.

Schulte M, Brecht-Krauss D, Werner M, Hartwig E, Sarkar MR, Keppler P, Kotzerke J, Guhlmann A, Delling G, Reske SN. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 1999; 40:1637–1643.PubMed

75.

Hawkins DS, Rajendran JG, Conrad EU 3rd, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-d-glucose positron emission tomography. Cancer 2002; 94:3277–3284.CrossRefPubMed

76.

Brenner W, Bohuslavizki KH, Eary JF. PET imaging of osteosarcoma. J Nucl Med 2003; 44:930–942.

77.

Lucas JD, O’Doherty MJ, Cronin BF, Marsden PK, Lodge MA, McKee PH, Smith MA. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg 1999; 86:550–556.CrossRefPubMed

78.

Lucas JD, O’Doherty MJ, Wong JC, Bingham JB, McKee PH, Fletcher CD, Smith MA. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br 1998; 80:441–447.PubMed

79.

Bredella MA, Caputo GR, Steinbach LS. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. AJR Am J Roentgenol 2002; 179:1145–1150.PubMed

80.

Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: positron emission tomogaphy with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996; 199:743–750.PubMed

81.

Shulkin BL, Wieland DM, Baro ME, Ungar DR, Mitchell DS, Dole MG, Rawwas JB, Castle VP, Sisson JC, Hutchinson RJ. PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med 1996; 37:16–21.

82.

Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001; 19:3397–3405.PubMed

83.

Brink L, Reinhardt MJ, Hoegerle S, Altehoefer C, Moser E, Nitzsche EU. Increased metabolic activity in the thymus gland studied with¹⁸F-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med 2001; 42:591–595.PubMed

84.

Yoon SN, Park CH, Kim MK, Hwang KH, Kim S. False-positive F-18 FDG gamma camera positron emission tomographic imaging resulting from inflammation of an anterior mediastinal mass in a patient with non-Hodgkin’s lymphoma. Clin Nucl Med 2001; 26:461–2PubMed

Title: Has PET become an important clinical tool in paediatric imaging?
Authors: Klaus Hahn
Thomas Pfluger
Publication date: 01-05-2004
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2004
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-004-1470-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Has PET become an important clinical tool in paediatric imaging?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2004

A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging

Subareolar injection of technetium-99m nanocolloid yields reliable data on the axillary lymph node tumour status in breast cancer patients with previous manipulations on the primary tumour: a prospective study of 117 patients

The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis

Nuclear Medicine Annual 2003

Estimating the input function non-invasively for FDG-PET quantification with multiple linear regression analysis: simulation and verification with in vivo data

Comparison of peritoneal equilibration test with 99mTc-DTPA excretion in the assessment of peritoneal permeability